Home > Neurology > ECTRIMS 2021 > Neuromyelitis Optica Spectrum Disorder (NMOSD) > Long-term efficacy of satralizumab for NMOSD

Long-term efficacy of satralizumab for NMOSD

Presented By
Dr Ingo Kleiter, Ruhr-Universität Bochum, Germany
Conference
ECTRIMS 2021
Trial
Phase 3, SAkuraStar, SAkuraSky
New, long-term data shows that more than 70% of patients with aquaporin-4 IgG-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) treated with satralizumab remained relapse-free after 4 years, with a favourable safety profile [1]. Satralizumab, a subcutaneously administered, IL-6 receptor antagonist, significantly reduced the risk of relapse in patients with AQP4-IgG+ NMOSD in the 2 double-blind, randomised-controlled, phase 3 SAkuraSky (NCT02028884) and SAkuraStar (NCT02073279) trials. In both trials, a favourable safety profile was observed in the double-blind phase [2,3]. The current study, presented by Dr Ingo Kleiter (Ruhr-Universität Bochum, Germany), assessed the long-term efficacy of satralizumab. Patients who rec...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on